Labiotech.eu’s Post

🌟 Exciting Partnership Announcement: NanoVation Therapeutics™ & Novo Nordisk 🌟 We are thrilled to share that NanoVation Therapeutics has partnered with Novo Nordisk to advance the development of groundbreaking genetic medicines! This collaboration combines NanoVation's cutting-edge long-circulating lipid nanoparticle (lcLNP) technology with Novo Nordisk’s expertise in cardiometabolic and rare diseases. Key Highlights: Funding & Potential: NanoVation will receive research funding and is eligible for up to $600 million in up-front and milestone payments, plus tiered royalties on future product sales. Focus: Development of base-editing therapies for rare genetic diseases and up to five additional targets for cardiometabolic and rare diseases. Exclusive License: Novo Nordisk secures an exclusive, worldwide license for NanoVation’s LNP technology for the lead programs. Dominik Witzigmann, NanoVation’s co-founder and CEO, emphasizes the significance of this partnership: “This agreement validates the potential of our LNP technologies to drive the next generation of life-changing genetic medicines.” Pieter Cullis, co-founder, adds, “Combining our expertise with Novo Nordisk's can create transformative therapies for challenging diseases.” Novo Nordisk’s Karina Thorn highlights the potential: “NanoVation’s innovative delivery platform could significantly advance our genetic medicine candidates.” Together, we aim to overcome the challenges of nucleic acid delivery and bring forward the next wave of revolutionary treatments. #Biotech #GeneticMedicine #Innovation #Partnership #LipidNanoparticles #GeneticTherapies #NanoVation #NovoNordisk

𝑰𝒏 𝒕𝒉𝒆 𝒆𝒗𝒆𝒓-𝒆𝒗𝒐𝒍𝒗𝒊𝒏𝒈 𝒍𝒂𝒏𝒅𝒔𝒄𝒂𝒑𝒆 𝒐𝒇 𝒅𝒓𝒖𝒈 𝒅𝒊𝒔𝒄𝒐𝒗𝒆𝒓𝒚, innovative technologies continually emerge to address complex challenges. Among these, CRISPR-Cas9 technology stands out as a transformative tool with profound implications for drug discovery research. By allowing precise genome editing in a variety of organisms, 𝑪𝑹𝑰𝑺𝑷𝑹 𝒉𝒂𝒔 𝒖𝒏𝒍𝒐𝒄𝒌𝒆𝒅 𝒏𝒆𝒘 𝒂𝒗𝒆𝒏𝒖𝒆𝒔 for understanding disease mechanisms, identifying therapeutic targets, and developing novel treatments. 𝐑𝐞𝐚𝐝 𝐅𝐮𝐥𝐥 𝐁𝐥𝐨𝐠: https://bit.ly/3UQMxfu 𝐄𝐦𝐚𝐢𝐥 𝐮𝐬 𝐚𝐭: info@worldbigroup.com #drugdiscovery #leadership #drugdiscoverys #medicinalchem #drugdiscovery #oncology #bioinformatics #genomics #industryblog #blog #medicinalchemistry #molecularbiology #antibodyengineering #drugdiscoveryconference #ddip #crispr #worldbievents #scienceresearch #ddip24

🚀 Early Bird Registration Now Open for Oligonucleotide Therapeutics and Delivery Conference 2025! 🚀 The Oligonucleotide Therapeutics and Delivery Conference 2025 is just around the corner, and early bird registration is now open! Don’t miss your chance to be part of this groundbreaking event, where you’ll have the opportunity to: 1. Learn from the Best: Attend keynote sessions and workshops led by top researchers and experts in the field of CRISPR technology. Gain valuable knowledge and insights into the latest advancements and applications. 2. Network with Peers: Connect with fellow scientists, industry professionals, and thought leaders during our dedicated networking sessions. Exchange ideas, discuss collaborations, and build lasting professional relationships. 3. Explore Innovative Solutions: Discover cutting-edge technologies and solutions at our exhibition area, where leading companies and research groups will showcase their latest products and innovations. 4. Participate in Engaging Discussions: Join interactive discussions and panels on critical topics related to Oligonucleotide Therapeutics, including ethical considerations, regulatory issues, and future directions in gene editing. Registration Link: https://lnkd.in/e4vBiCpT Why Register Early? By registering early, you’ll secure your spot at this highly anticipated event and benefit from discounted rates. Early registration also ensures you have access to all the exciting sessions and networking opportunities that the conference has to offer. Get Involved: We invite you to be part of this transformative event. Follow our page for ongoing updates and announcements, and feel free to reach out if you have any questions. We look forward to seeing you at Oligonucleotide Therapeutics and Delivery Conference 2025! #OTDC2025 #EarlyBirdRegistration #Networking #GeneEditing #Biotechnology #Oligonucleotides #OligocmcandRegulatory #EmergingmRNATherapeutics #Immunology #microRNA #RNAediting #NucleicAcidTherapeutics #ClinicalResearch #RNAandoligoTherapeutics #RNATherapeutics #CRISPR #Aptamers #OligochemistryToolsandTechnologies #Toxicity #rnai #geneediting #genetherapy #sirna #lna #splicing #delivery #systems #drugs #pharmacokinetics #dynamics #pharmacology #drugresearch #drugsafety #drugdiscovery #drugdevelopment #therapeutics #genes #coding #rna #conference #researchers #rome #italy #speakers #hybrid #online #keynotespeaker #presentation #oral #sharethispost

Delve deeper into the fascinating world of drug discovery at the Medicinal Chemistry Strategy Meeting in Princeton or San Diego! This article explores: 👉 Target identification: Unraveling the biological puzzles at the heart of disease. 👉 Harnessing data: How big data and bioinformatics are revolutionizing target selection. 👉 Validation techniques: Bridging the gap between theory and practice in drug development. 👉 Hit discovery: Navigating the path from targets to potential drug candidates. 👉 Screening paradigms and assay development: Unveiling promising molecules for further investigation. Ready to unlock the future of medicine? Join us at the Strategy Meeting to: ✅ Gain insights from leading experts: Learn about the latest advancements in drug discovery. ✅ Network with peers: Collaborate with fellow researchers and accelerate innovation. ✅ Explore real-world applications: Discover how groundbreaking research translates into life-saving treatments. Don't miss this opportunity! Register for Princeton - https://lnkd.in/dsFEG5MA Register for San Diego- https://lnkd.in/gnMhB3VY Secure your spot now! #DrugDiscovery #TargetIdentification #HitDiscovery #MedicinalChemistry #DrugDevelopment #HealthcareInnovation

The journey from target identification to hit discovery represents a testament to the ingenuity and perseverance of the scientific community. By harnessing cutting-edge technologies and interdisciplinary collaboration, researchers continue to unravel the complexities of disease biology, paving the way for the development of transformative therapeutics. https://lnkd.in/gh3z5ESx #drugdiscovery #targetidentification #drugcandidate #bioinformatics #phenotypicscreening #monoclonalantibodies #mabs #targetvalidation #antisense #transgenic #throughput #assay #leadoptimization

"As we delve into the emerging field of the #DarkGenome, I'm excited to share views with Nature Biotechnology on the pioneering work we're undertaking at Hervolution Therapeutics. Our proprietary technology is not just unlocking these elusive targets but is also redefining immune system tolerance. It's a privilege to lead the charge in this new frontier, targeting antigens like #HERVs that were once hidden, but now are emerging into the spotlight. #JoinTheHervolution #HealthcareOfTomorrow" https://lnkd.in/dwrS9uBB

Exciting news in bioprocessing! Earlier this month MilliporeSigma officially opened its cutting-edge viral clearance facility in Rockville, Maryland. This new facility is a game-changer, designed to significantly reduce the time required for viral safety testing—a critical step in the development of biologics and gene therapies. 🔬 Traditionally, viral clearance testing could take weeks, but Millipore’s new facility cuts that time dramatically. This accelerated timeline is set to help biopharma companies get life-saving therapies to market faster, which is especially crucial in areas like cancer, rare diseases, and pandemic response. 🪨 The Rockville site is equipped with state-of-the-art tech and offers tailored solutions to meet the specific needs of biopharma companies, supporting their goal of speeding up innovation without compromising safety. 🌎 As the demand for biopharmaceuticals continues to rise, having facilities like this will be key to meeting global needs efficiently and safely. MilliporeSigma’s investment is a strong signal of the industry's commitment to advancing biologics production. #Bioprocessing #Biotechnology #ViralClearance #GeneTherapy #Biopharma #MilliporeSigma #Innovation #Facilities

In the ever-evolving landscape of drug discovery, innovative technologies continually emerge to address complex challenges. Among these, 𝐂𝐑𝐈𝐒𝐏𝐑-𝐂𝐚𝐬9 𝐭𝐞𝐜𝐡𝐧𝐨𝐥𝐨𝐠𝐲 𝐬𝐭𝐚𝐧𝐝𝐬 𝐨𝐮𝐭 𝐚𝐬 𝐚 𝐭𝐫𝐚𝐧𝐬𝐟𝐨𝐫𝐦𝐚𝐭𝐢𝐯𝐞 𝐭𝐨𝐨𝐥 with profound implications for drug discovery research. By allowing precise genome editing in a variety of organisms, CRISPR has unlocked new avenues for understanding disease mechanisms, identifying therapeutic targets, and developing novel treatments. 𝐑𝐞𝐚𝐝 𝐅𝐮𝐥𝐥 𝐁𝐥𝐨𝐠:https://bit.ly/3Q5Sjbw 𝐄𝐦𝐚𝐢𝐥 𝐮𝐬 𝐚𝐭 : info@worldbigroup.com #drugdiscovery #innovation #genomics #sciencestudent #steam #scientist #phdresearch #biologics #medicinalchem #drugdiscovery #oncology #bioinformatics #genomics #medicinalchemistry #licensing #drugdiscoveryconference2024 #ddip24

🚀 Exciting Partnership Unveiled! Remix Therapeutics joins forces with Roche for pioneering discoveries in small molecule therapeutics modulating RNA processing using the REMaster™ platform. 🧬💊 🌐 Remix, a clinical-stage biotech, will receive $30 million upfront, with potential milestone payments totaling up to $1 billion, plus royalties. In return, Roche gains exclusive rights to specific targets, marking a strategic collaboration to advance RNA-level interventions in disease treatment. 💡👥 👨🔬 Peter Smith, CEO of Remix, expresses enthusiasm about leveraging REMaster's capabilities, stating, "Our collaboration with Roche provides an opportunity to further translate our cutting-edge science into new medicines." 🌱 🌐 James Sabry, Global Head of Roche Pharma Partnering, highlights Remix's scientific prowess, emphasizing the alignment with Roche's strategy to innovate in areas with high unmet medical needs. 🤝🔍 🔬 Remix Therapeutics, with its REMaster platform, aims to reprogram RNA processing to alter gene expression fundamentally—a potential game-changer in addressing disease drivers at their root. 🌍🔬 💬 Stay tuned for groundbreaking developments as Remix and Roche redefine the landscape of small molecule therapeutics! 💪🌐 #RemixTherapeutics #RocheCollaboration #RNAProcessing #BiotechInnovation #HealthcarePartnership #DrugDiscovery #MedicalAdvancements #InnovationInMedicine #Biopharma #REMmasterPlatform #LinkedInNews 🌐👩⚕️

𝐀𝐥𝐥𝐨𝐠𝐞𝐧𝐞 & 𝐀𝐫𝐛𝐨𝐫 𝐏𝐚𝐫𝐭𝐧𝐞𝐫 𝐟𝐨𝐫 𝐍𝐞𝐱𝐭-𝐆𝐞𝐧 𝐀𝐥𝐥𝐨𝐂𝐀𝐑 𝐓 𝐓𝐡𝐞𝐫𝐚𝐩𝐲 𝐢𝐧 𝐀𝐮𝐭𝐨𝐢𝐦𝐦𝐮𝐧𝐞 𝐃𝐢𝐬𝐞𝐚𝐬𝐞 Allogene Therapeutics, Inc. (Nasdaq: ALLO) Allogene Therapeutics and Arbor Biotechnologies, Inc. Arbor Biotechnologies announce a global gene editing licensing agreement for Allogene's next generation AlloCAR T platform for autoimmune disease (AID) treatment. Zachary Roberts, M.D., Ph.D. Zachary Roberts, of Allogene, highlights the potential of CAR T therapy for AID and the importance of differentiation for success. The agreement grants Allogene access to Arbor's CRISPR gene-editing technology for developing effective CAR T approaches. Allogene's expertise in CAR T R&D aims to create next-generation allogeneic CAR T products with reduced or chemotherapy-free conditioning. Their first AID AlloCAR T investigational product is set to enter Phase 1 clinical trials in early 2025. Devyn Smith, Ph.D. Devyn Smith, CEO of Arbor Arbor Biotechnologies, emphasizes the collaboration's goal of leveraging gene-editing technologies to advance novel CAR T therapeutics for autoimmune diseases. #AllogeneTherapeutics #ArborBiotechnologies #geneediting #celltherapy #autoimmunedisease #CRISPR #clinicaltrials #biotechnology